Fabrazyme® (agalsidase beta)

For intravenous infusion

DESCRIPTION

Fabrazyme® (agalsidase beta) is a recombinant human α-galactosidase A enzyme with the same amino acid sequence as the native enzyme. Purified agalsidase beta is a homodimeric glycoprotein with a molecular weight of approximately 100 kD. The mature protein is comprised of two subunits of 398 amino acids (approximately 51 kD), each of which contains three N-linked glycosylation sites. α-galactosidase A catalyzes the hydrolysis of globotriaosylceramide (GL-3) and other α-galactyl-terminated neutral glycosphingolipids, such as galabiosylceramide and blood group B substances to ceramide dihexoside and galactose. The specific activity of Fabrazyme is approximately 70 U/mg (one unit is defined as the amount of activity that results in the hydrolysis of 1 μmole of a synthetic substrate, p-nitrophenyl-α-D-galactopyranoside, per minute under the assay conditions).

Fabrazyme is produced by recombinant DNA technology in a Chinese Hamster Ovary mammalian cell expression system.

Fabrazyme is intended for intravenous infusion. It is supplied as a sterile, nonpyrogenic, white to off-white, lyophilized cake or powder for reconstitution with Sterile Water for Injection, USP. Each 35 mg vial contains 37 mg of agalsidase beta as well as 222 mg mannitol, 20.4 mg sodium phosphate monobasic monohydrate, and 59.2 mg sodium phosphate dibasic heptahydrate. Following reconstitution as directed, 35 mg of agalsidase beta (7 mL) may be extracted from each 35 mg vial.

Each 5 mg vial contains 5.5 mg of agalsidase beta as well as 33.0 mg mannitol, 3.0 mg sodium phosphate monobasic monohydrate, and 8.8 mg sodium phosphate dibasic heptahydrate. Following reconstitution as directed, 5 mg of agalsidase beta (1 mL) may be extracted from each 5 mg vial.

CLINICAL PHARMACOLOGY

Mechanism of Action

Fabry disease is an X-linked genetic disorder of glycosphingolipid metabolism. Deficiency of the lysosomal enzyme α-galactosidase A leads to progressive accumulation of glycosphingolipids, predominantly GL-3, in many body tissues, starting early in life and continuing over decades. Clinical manifestations of Fabry disease include renal failure, cardiomyopathy, and cerebrovascular accidents. Accumulation of GL-3 in renal endothelial cells may play a role in renal failure.

Fabrazyme is intended to provide an exogenous source of α-galactosidase A in Fabry

disease patients. Preclinical and clinical studies evaluating a limited number of cell types indicate that Fabrazyme will catalyze the hydrolysis of glycosphingolipids including GL-3.

Pharmacokinetics

Plasma pharmacokinetic profiles of Fabrazyme were characterized at 0.3, 1.0 and 3.0 mg/kg in adult patients with Fabry disease. The area under the plasma concentration-time curve (AUC_∞) and the clearance (CL) did not increase proportionately with increasing doses, demonstrating that the enzyme follows non-linear pharmacokinetics (**Table 1**). Plasma pharmacokinetic profiles were also characterized in adult patients with Fabry disease given 1.0 mg/kg Fabrazyme every 14 days for a total of 11 infusions. Refer to **Table 1** below for more details.

In 15 pediatric Fabry patients (ranging in age from 8 to 16 years old and weighing between 27.1 to 64.9 kg) who were dosed with 1.0 mg/kg every 14 days, Fabrazyme pharmacokinetics were not weight-dependent (**Table 1**). Fabrazyme concentrations were about 5-times higher after IgG seroconversion, without any detectable impact on GL-3 clearance.

IgG seroconversion in pediatric patients was associated with prolonged half-life and plasma concentrations of Fabrazyme, a phenomenon rarely observed in adult patients. A possible cause for this prolongation likely pertains to the ability of antibodies to potentially act as “carriers” for their antigens. (see **ADVERSE REACTIONS: Immunogenicity and PRECAUTIONS: Pediatric Use**).

57

Table 1: Fabrazyme Pharmacokinetic Summary

Dose	Regimen	Mean Infusion Length (min)	Infusion number (n= patients)	AUC(0-∞) μg min/mL	Cmax μg/mL	Half-life min	CL mL/min/kg	Vss* mL/kg
Study FB9702-01: Phase 1/2 Study in Adult patients with Fabry Disease								
0.3 mg/kg	q14 days ×5	132	1 (n = 3)	79 ± 24	0.6 ± 0.2	92 ± 27	4.1 ± 1.2	225 ± 62
		128	5 (n = 3)	74 ± 30	0.6 ± 0.2	78 ± 67	4.6 ± 2.2	330 ± 231
1.0 mg/kg	q14 days × 5	115	1 (n = 3)	496 ± 137	5.0 ± 1.1	67 ± 12	2.1 ± 0.7	112 ± 13
		120	5 (n = 2)	466 ± 382	4.74 ± 4.3	45 ± 3	3.2 ± 2.6	243 ± 236
3.0 mg/kg	q14 days × 5	129	1 (n = 2)	4168 ± 1401	29.7 ± 14.6	102 ± 4	0.8 ± 0.3	81 ± 45
		300	5 (n = 2)	4327 ± 2074	19.8 ± 5.8	87 ± 21	0.8 ± 0.4	165 ± 80
Study AGAL-1-002-98: Phase 3 Study in Adult Patients with Fabry Disease								
1.0 mg/kg	q14 days x 11	280	1-3 (n = 11)	649 ± 226	3.5 ± 1.6	89 ± 20	1.8 ± 0.8	120 ± 80
		280	7 (n = 11)	372 ± 223	2.1 ± 1.14	82 ± 25	4.9 ± 5.6	570 ± 710
		300	11 (n = 11)	784 ± 521	3.5 ± 2.2	119 ± 49	2.3 ± 2.2	280 ± 230
Study AGAL-016-01: Phase 2 Study in Pediatric Patients with Fabry Disease								
1.0 mg/kg	q14 days × 24	208	1 (n = 8-9)	344 ± 307	2.2 ± 1.9	86 ± 27	5.8 ± 4.6	1097 ± 912
		111	12 (n = 15)	1007 ± 688	4.9 ± 2.4	130 ± 41	1.6 ± 1.2	292 ± 185
		108	24 (n = 9-10)	1238 ± 547	7.1 ± 4.4	151 ± 59	1.1 ± 0.8	247 ± 146

All data reported as the mean ± standard deviation.
*Vss = volume of distribution at steady state

58

CLINICAL STUDIES

The safety and efficacy of Fabrazyme were assessed in a randomized, double-blind, placebo-controlled, multinational, multicenter study of 58 Fabry patients (56 males and 2 females), ages 16 to 61 years, all naïve to enzyme replacement therapy. Patients received either 1.0 mg/kg of Fabrazyme or placebo every two weeks for five months (20 weeks) for a total of 11 infusions. All patients were pretreated with acetaminophen and an antihistamine to decrease or prevent infusion associated reactions. Oral steroids were an additional option to the pretreatment regimen for patients who exhibited severe or recurrent infusion reactions. The primary efficacy endpoint of GL-3 inclusions in renal interstitial capillary endothelial cells, was assessed by light microscopy and was graded on an inclusion severity score ranging from 0 (normal or near normal) to 3 (severe inclusions).

A GL-3 inclusion score of 0 was achieved in 20 of 29 (69%) patients treated with Fabrazyme compared to 0 of 29 treated with placebo ($p<0.001$). Similar reductions in GL-3 inclusions were observed in the capillary endothelium of the heart and skin (**Table 2**). No differences between groups in symptoms or renal function were observed during this five month study.

Table 2
Reduction of GL-3 Inclusions to Normal or Near Normal Levels (0 Score) in the Capillary Endothelium of the Kidney, Heart, and Skin

	5 Months of the Controlled Study		**6 Months of the Open-label Extension Study**	
	Placebo (n=29)	**Fabrazyme** (n=29)	**Placebo/ Fabrazyme** (n=29)*	**Fabrazyme/ Fabrazyme** (n=29)*
Kidney	0/29	20/29	24/24	23/25
Heart	1/29	21/29	13/18	19/22
Skin	1/29	29/29	25/26	26/27

* Results reported where biopsies were available

All 58 patients in the randomized study participated in an open-label extension study of Fabrazyme at 1.0 mg/kg every two weeks, which continued for an additional 54 months. At the end of six months of open-label treatment, most patients achieved a GL-3 inclusion score of 0 in capillary endothelium (**Table 2**). GL-3 was decreased to normal or near normal levels in mesangial cells, glomerular capillary endothelium, interstitial cells, and non-capillary endothelium. GL-3 deposition was still present in vascular smooth muscle cells, tubular epithelium and podocytes, at variably reduced levels. Forty-four of the 58 patients completed 54 months of the open-label extension study.

Thirty-six of these 44 patients underwent follow-up skin biopsy, and 31 of these patients showed sustained GL-3 clearance in the capillary endothelium of the skin. Follow-up heart and kidney biopsies were assessed in only 8 of the 44 patients, which showed sustained GL-3 clearance in the capillary endothelium of the kidney in 8 patients, and sustained GL-3 clearance in the capillary endothelium of the heart in 6 patients. Plasma GL-3 levels were reduced to normal levels (≤7.03 μg/mL) and remained at normal levels after up to 60 months of treatment. The reduction of GL-3 inclusions suggests that Fabrazyme may ameliorate disease expression; however, the relationship of GL-3 inclusion reduction to specific clinical manifestations of Fabry disease has not been established.

The safety and efficacy of Fabrazyme were assessed in a multinational, multicenter, uncontrolled, open-label study in 16 pediatric patients with Fabry disease (see **PRECAUTIONS: Pediatric Use**).

The safety of Fabrazyme was evaluated in an open-label, rechallenge study in patients who had a positive skin test to Fabrazyme or who had tested positive for Fabrazyme-specific IgE antibodies. In this study, 6 adult male patients, who had experienced multiple or recurrent infusion reactions during previous clinical trials with Fabrazyme, were rechallenged with Fabrazyme administered as a graded infusion, for up to 52 weeks of treatment (see **ADVERSE REACTONS: Immunogenicity and Rechallenge**). The initial two rechallenge doses of Fabrazyme were administered as a 0.5 mg/kg dose per week at an initial infusion rate of 0.01 mg/min for the first 30 minutes ($1/25^{th}$ the usually recommended maximum infusion rate). The infusion rate was doubled every 30 minutes thereafter, as tolerated, for the remainder of the infusion up to a maximum rate of 0.25 mg/min. If the patient tolerated the infusion, the dose was increased to 1.0 mg/kg every two weeks (usually recommended dose), and the infusion rate was increased by slow titration upwards (see **DOSAGE and ADMINISTRATION**).

Four of the six patients treated in this study received at least 26 weeks of study medication, and two patients discontinued prematurely due to recurrent infusion reactions (see **PRECAUTIONS: Immunogenicity and Rechallenge).**

INDICATIONS AND USAGE

Fabrazyme (agalsidase beta) is indicated for use in patients with Fabry disease. Fabrazyme reduces globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types (see **CLINICAL STUDIES**).

CONTRAINDICATIONS

No known contraindications.

WARNINGS

Infusion Reactions

Infusion reactions have been observed in many patients during Fabrazyme infusions (see **ADVERSE REACTIONS**). Some of the reactions were severe. Severe infusion reactions experienced by more than one patient in clinical studies with Fabrazyme included chills, vomiting, hypotension, and paresthesia. Other infusion reactions included pyrexia, feeling hot or cold, dyspnea, nausea, flushing, headache, fatigue, pruritus, pain in extremity, hypertension, chest pain, throat tightness, abdominal pain, dizziness, tachycardia, nasal congestion, diarrhea, edema peripheral, myalgia, urticaria, bradycardia, and somnolence. All patients were pretreated with acetaminophen. Infusion reactions occurred in some patients after receiving pretreatment with antipyretics, antihistamines, and oral steroids. Infusion reactions declined in frequency with continued use of Fabrazyme. However, infusion reactions may still occur despite extended duration of Fabrazyme treatment.

Patients should be given antipyretics prior to infusion. If an infusion reaction occurs, regardless of pretreatment, decreasing the infusion rate, temporarily stopping the infusion, and/or administration of additional antipyretics, antihistamines, and/or steroids may ameliorate the symptoms. Because of the potential for severe infusion reactions, appropriate medical support measures should be readily available when Fabrazyme is administered.

PRECAUTIONS

General

Patients with advanced Fabry disease may have compromised cardiac function, which may predispose them to a higher risk of severe complications from infusion reactions (see **WARNINGS: Infusion Reactions**). Patients with compromised cardiac function should be monitored closely if the decision is made to administer Fabrazyme.

Immunogenicity and Rechallenge

Most patients develop IgG antibodies to Fabrazyme (see **ADVERSE REACTIONS: Immunogenicity**). A few patients developed IgE or skin test reactivity specific to Fabrazyme. Physicians should consider testing for IgE (see **PRECAUTIONS: Laboratory Tests**) in patients who experienced suspected allergic reactions and consider the risks and benefits of continued treatment in patients with anti- Fabrazyme IgE.

Patients who have had a positive skin test to Fabrazyme or who have tested positive for Fabrazyme-specific IgE antibody have been rechallenged with Fabrazyme using a rechallenge protocol (see **CLINICAL STUDIES**). Two of six patients in the rechallenge study discontinued treatment with Fabrazyme prematurely due to recurrent infusion reactions. Four serious infusion reactions occurred in three patients during Fabrazyme infusions, including bronchospasm, urticaria, hypotension, and development of

Fabrazyme-specific antibodies. Other infusion-related reactions occurring in more than one patient during the study included rigors, hypertension, nausea, vomiting, and pruritus. Rechallenge of these patients should only occur under the direct supervision of qualified personnel, with appropriate medical support measures readily available.

Information for Patients

Patients should be informed that a Registry has been established in order to better understand the variability and progression of Fabry disease in the population as a whole and in women (see **PRECAUTIONS: Responses in Women**), and to monitor and evaluate long-term treatment effects of Fabrazyme. The Registry will also monitor the effect of Fabrazyme on pregnant women and their offspring, and determine if Fabrazyme is excreted in breast milk. Patients should be encouraged to participate and advised that their participation is voluntary and may involve long-term follow-up. For more information visit www.fabryregistry.com or call (800) 745-4447.

Laboratory Tests

There are no marketed tests for antibodies against Fabrazyme. If testing is warranted, contact your local Genzyme representative or Genzyme Corporation at (800) 745-4447.

Drug Interactions

No drug interaction studies were performed.

No *in vitro* metabolism studies were performed.

Carcinogenesis, Mutagenesis, Impairment of Fertility

There are no animal or human studies to assess the carcinogenic or mutagenic potential of Fabrazyme. There are no studies assessing the potential effect of Fabrazyme on fertility in humans.

Pregnancy: Category B

Reproduction studies have been performed in rats at doses up to 30 times the human dose and have revealed no evidence of impaired fertility or negative effects on embryo fetal development due to Fabrazyme. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Women of childbearing potential should be encouraged to enroll in the Fabry patient registry (see **PRECAUTIONS: Information for Patients**).

Nursing Mothers

It is not known whether Fabrazyme is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Fabrazyme is administered to a nursing woman.

Nursing mothers should be encouraged to enroll in the Fabry registry (see **PRECAUTIONS: Information for Patients**).

Responses in Women

Fabry disease is an X-linked genetic disorder. However, some heterozygous women will develop signs and symptoms of Fabry disease due to the variability of the X-chromosome inactivation within cells.

A total of twelve adult female patients with Fabry disease were enrolled in two separate randomized, double-blind, placebo-controlled clinical studies with Fabrazyme, and two female pediatric patients with Fabry disease, ages 11 years, were evaluated in an open-label, uncontrolled pediatric study (see **PRECAUTIONS: Pediatric Use**). Although the safety and efficacy data available in female patients in these clinical studies are limited, there is no indication that female patients respond differently to Fabrazyme than do males.

Pediatric Use

The safety and efficacy of Fabrazyme were assessed in a multinational, multicenter, uncontrolled, open-label study to evaluate safety, pharmacokinetics, and pharmacodynamics in 16 pediatric patients with Fabry disease (14 males, 2 females) who

were ages 8 to 16 years at first treatment. All patients received Fabrazyme 1 mg/kg every 2 weeks for up to 48 weeks. At Baseline, all 14 males had elevated plasma GL-3 levels (i.e., >7.03 µg/mL), whereas the two female patients had normal plasma GL-3 levels. Twelve of the 14 male patients, and no female patients, had GL-3 inclusions observed in the capillary endothelium on skin biopsies at Baseline. At Weeks 24 and 48 of treatment, all 14 males had plasma GL-3 within the normal range. The 12 male patients with GL-3 inclusions in capillary endothelium at Baseline achieved GL-3 inclusion scores of 0 at Weeks 24 and 48 of treatment. The two female patients' plasma GL-3 levels remained normal through study Week 48. No new safety concerns were identified in pediatric patients in this study, and the overall safety and efficacy profile of Fabrazyme treatment in pediatric patients was found to be consistent with that seen in adults. Immunologic responses in pediatric patients may differ from those in adults, as IgG seroconversion in pediatric patients was associated with prolonged half-life concentrations of Fabrazyme, a phenomenon rarely observed in adult patients (see **CLINICAL PHARMACOLOGY: Pharmacokinetics**, and **ADVERSE REACTIONS: Immunogenicity**).

Patients younger than 8 years of age were not included in clinical studies. The safety and efficacy in patients younger than 8 years of age have not been evaluated.

Geriatric Use

Clinical studies of Fabrazyme did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

ADVERSE REACTIONS

The most serious and most common adverse reactions reported with Fabrazyme are infusion reactions (see **WARNINGS: Infusion Reactions**). Serious and/or frequently occurring (≥ 5% incidence) related adverse reactions, including infusion reactions, consisted of one or more of the following events: chills, pyrexia, feeling hot or cold, dyspnea, nausea, flushing, headache, vomiting, paresthesia, fatigue, pruritus, pain in extremity, hypertension, chest pain,throat tightness, abdominal pain, dizziness, tachycardia, nasal congestion, diarrhea, edema peripheral, myalgia, back pain, pallor, bradycardia, urticaria, hypotension, face edema, rash, and somnolence. The occurrence of somnolence can be attributed to clinical trial specified pre-treatment with antihistamines.

Other reported serious adverse events included stroke, pain, ataxia, bradycardia, cardiac arrhythmia, cardiac arrest, decreased cardiac output, vertigo, hypoacousia, and nephrotic syndrome. These adverse events also occur as manifestations of Fabry disease; an alteration in frequency or severity cannot be determined from the small numbers of patients studied.

The data described below reflect exposure of 80 patients, ages 16 to 61 years, to 1.0 mg/kg Fabrazyme every two weeks in two separate double-blind, placebo-controlled clinical trials, for periods ranging from 1 to 35 months (mean 15.5 months). All 58 patients enrolled in one of the two studies continued into an open-label extension study of Fabrazyme treatment for up to 54 additional months. Patients were treated with antipyretics and antihistamines prior to the infusions.

Because clinical trials are conducted under widely varying and controlled conditions, the observed adverse reaction rates may not predict the rates observed in patients in clinical practice.

Table 3 enumerates treatment-emergent adverse events (regardless of relationship) that occurred during the double-blind treatment periods of the two placebo-controlled trials. Reported adverse events have been classified by Medical Dictionary for Regulatory Activities (MedDRA) terminology System Organ Class and Preferred Term.

Table 3
Summary of Adverse Events Occurring in at least 5% of Patients treated with Fabrazyme in Placebo-Controlled Studies

MedDRA System Organ Class/ Preferred Term	**Fabrazyme n = 80 (%)**	**Placebo n = 60 (%)**
Blood and Lymphatic System Disorders		
Anaemia	11 (14)	8 (13)
Cardiac Disorders		
Tachycardia	4 (5)	2 (3)
Ventricular Wall Thickening	4 (5)	1 (2)
Ear and Labyrinth Disorders		
Hypoacusis	4 (5)	0
Tinnitus	6 (8)	2 (3)
Gastrointestinal Disorders		
Stomach discomfort	5 (6)	1(2)
Toothache	5 (6)	2 (3)
Vomiting	19 (24)	14 (23)
General Disorders and Administration Site Conditions		
Adverse event	8 (10)	3 (5)
Chest discomfort	4 (5)	1 (2)
Chills	34 (43)	8 (13)
Fatigue	20 (25)	10 (17)
Feeling cold	8 (10)	1 (2)
Oedema peripheral	17 (21)	4 (7)
Pain	13 (16)	8 (13)
Pyrexia	29 (36)	12 (20)
Infections and Infestations		
Bronchitis	6 (8)	3 (5)
Fungal infection	4 (5)	0
Lower respiratory tract infection	9 (11)	1 (2)
Nasopharyngitis	22 (28)	9 (15)
Pharyngitis	5 (6)	1 (2)
Sinusitis	7 (9)	2 (3)
Upper respiratory tract infection	15 (19)	6 (10)
Viral infection	4 (5)	0
Viral upper respiratory infection	5 (6)	1 (2)
Injury, Poisoning and Procedural Complications		
Excoriation	7 (9)	1 (2)
Fall	5 (6)	2 (3)
Post-procedural hemorrhage	4 (5)	1 (2)
Procedural pain	20 (25)	12 (20)
Investigations		
Blood bicarbonate decreased	7 (9)	4 (7)
Blood creatinine increased	7 (9)	3 (5)
Blood pressure increased	8 (10)	2 (3)
Body temperature increased	5 (6)	1 (2)

Table 3

Summary of Adverse Events Occurring in at least 5% of Patients treated with Fabrazyme in Placebo-Controlled Studies (continued)

MedDRA System Organ Class/ Preferred Term	Fabrazyme n = 80 (%)	Placebo n = 60 (%)
Musculoskeletal and Connective Tissue Disorders		
Back pain	13 (16)	6 (10)
Muscle spasms	4 (5)	1 (2)
Myalgia	6 (8)	2 (3)
Neck pain	4 (5)	1 (2)
Pain in extremity	15 (19)	5 (8)
Nervous System Disorders		
Burning sensation	5 (6)	0
Dizziness	17 (21)	6 (10)
Headache	31 (39)	17 (28)
Hypoaesthesia	7 (9)	5 (8)
Paraesthesia	25 (31)	11 (18)
Psychiatric Disorders		
Anxiety	6 (8)	3 (5)
Depression	5 (6)	1 (2)
Insomnia	7 (9)	4 (7)
Renal and Urinary Disorders		
Proteinuria	4 (5)	2 (3)
Respiratory, Thoracic and Mediastinal Disorders		
Cough	26 (33)	15 (25)
Dyspnoea	6 (8)	1 (2)
Nasal congestion	15 (19)	9 (15)
Pharyngolaryngeal pain	13 (16)	9 (15)
Respiratory tract congestion	6 (8)	1 (2)
Wheezing	5 (6)	0
Skin and Subcutaneous Tissue Disorders		
Dermatitis contact	4 (5)	1 (2)
Pruritus	6 (8)	3 (5)
Rash	8 (10)	5 (8)
Vascular Disorders		
Hypertension	4 (5)	2 (3)

Observed adverse events in the Phase 1/2 study and the open-label treatment period for the extension study following the controlled study were not different in nature or intensity.

The safety profile of Fabrazyme in pediatric Fabry disease patients, ages 8 to 16 years, was found to be consistent with that seen in adults (see **PRECAUTIONS: Pediatric Use**). The safety of Fabrazyme in patients younger than 8 years of age has not been evaluated.

Immunogenicity

Ninety-five of 121 (79%) adult patients and 11 of 16 (69%) pediatric patients (106 of 137, 74% of all patients) treated with Fabrazyme in clinical studies have developed IgG antibodies to Fabrazyme. Most patients who develop IgG antibodies do so within the first 3 months of exposure. IgG seroconversion in pediatric patients was associated with prolonged half-life of Fabrazyme, a phenomenon rarely observed in adult patients (see **CLINICAL PHARMACOLOGY: Pharmacokinetics** and **PRECAUTIONS: Pediatric Use**). A possible cause for this prolongation likely pertains to the ability of antibodies to act as "carriers" for their antigens. Among the 14 female patients exposed to Fabrazyme in clinical studies, four (two adult and two pediatric patients) developed IgG antibodies to Fabrazyme.

IgG antibodies to Fabrazyme were purified from 15 patients with high antibody titers (≥ 12,800) and studied for inhibition of *in vitro* enzyme activity. Under the conditions of this assay, most of these 15 patients had inhibition of *in vitro* enzyme activity ranging between 21-74% at one or more timepoints during the study. Assessment of inhibition of enzyme uptake in cells has not been performed. No general pattern was seen in individual patient reactivity over time. The clinical significance of binding and/or inhibitory antibodies to Fabrazyme is not known. In patients followed in the open-label extension study, reduction of GL-3 in plasma and GL-3 inclusions in superficial skin capillaries was maintained after antibody formation.

The data reflect the percentage of patients whose test results were considered positive for antibodies to Fabrazyme using an ELISA and radioimmunoprecipitation (RIP) assay for antibodies. These results are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibodies in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of the incidence of antibodies to Fabrazyme with the incidence of antibodies to other products may be misleading.

Testing for IgE was performed in approximately 60 patients in clinical trials who experienced moderate to severe infusion reactions or in whom mast cell activation was suspected. Seven of these patients tested positive for Fabrazyme-specific IgE antibodies

or had a positive skin test to Fabrazyme. Patients who have had a positive skin test to Fabrazyme, or who have tested positive for Fabrazyme-specific IgE antibodies in clinical trials with Fabrazyme have been rechallenged (see **CLINICAL STUDIES, PRECAUTIONS: Immunogenicity and Rechallenge** and **DOSAGE AND ADMINISTRATION**).

OVERDOSAGE

There have been no reports of overdose with Fabrazyme. In clinical trials, patients received doses up to 3.0 mg/kg body weight.

DOSAGE AND ADMINISTRATION

The recommended dosage of Fabrazyme is 1.0 mg/kg body weight infused every 2 weeks as an IV infusion. Patients should receive antipyretics prior to infusion (see **WARNINGS: Infusion Reactions**).

The initial IV infusion rate should be no more than 0.25 mg/min (15 mg/hr). The infusion rate may be slowed in the event of infusion reactions. After patient tolerance to the infusion is well established, the infusion rate may be increased in increments of 0.05 to 0.08 mg/min (increments of 3 to 5 mg/hr) with each subsequent infusion. For patients weighing < 30 kg, the maximum infusion rate should remain at 0.25 mg/min (15 mg/hr). For patients weighing ≥30 kg, the administration duration should not be less than 1.5 hours (based on individual patient tolerability).

Patients who have had a positive skin test to Fabrazyme or who have tested positive for anti-Fabrazyme IgE may be successfully re-challenged with Fabrazyme. The initial re-challenge administration should be a low dose at a lower infusion rate e.g., 1/2 the therapeutic dose (0.5 mg/kg) at 1/25 the initial standard recommended rate (0.01 mg/min) Once a patient tolerates the infusion, the dose may be increased to reach the approved dose of 1.0 mg/kg and the infusion rate may be increased by slowly titrating upwards (doubled every 30 minutes up to a maximum rate of 0.25 mg/min), as tolerated.

Instructions for Use

Fabrazyme does not contain any preservatives. Vials are for single-use only. Any unused product should be discarded.

Shaking or agitation of this product should be avoided. Do not use filter needles during the preparation of the infusion.

Reconstitution and Dilution (using Aseptic Technique)

1. Fabrazyme vials and diluent should be allowed to reach room temperature prior to reconstitution (approximately 30 minutes). The number of 35 mg and 5 mg vials needed is based on the patient's body weight (kg) and the recommended dose of 1.0

mg/kg.

Select a combination of 35 mg and 5 mg vials so that the total number of mg is equal to or greater than the patient's number of kg of body weight.

2. Reconstitute each 35 mg vial of Fabrazyme by slowly injecting 7.2 mL of Sterile Water for Injection, USP down the inside wall of each vial. Roll and tilt each vial gently. Each vial will yield a 5.0 mg/mL clear, colorless solution (total extractable amount per vial is 35 mg, 7.0 mL).

   Reconstitute each 5 mg vial of Fabrazyme by slowly injecting 1.1 mL of Sterile Water for Injection, USP down the inside wall of each vial. Roll and tilt each vial gently. Each vial will yield a 5.0 mg/mL clear, colorless solution (total extractable amount per vial is 5 mg, 1.0 mL).

3. Visually inspect the reconstituted vials for particulate matter and discoloration. Do not use the reconstituted solution if there is particulate matter or if it is discolored.

4. The reconstituted solution should be further diluted with 0.9% Sodium Chloride Injection, USP to total volume based on patient weight specified in **Table 4** below. Prior to adding the volume of reconstituted Fabrazyme required for the patient dose, remove an equal volume of 0.9% Sodium Chloride for Injection, USP from the infusion bag.

Table 4

Patient Weight (kg)	Minimum Total Volume
≤35	50
35.1 – 70	100
70.1 – 100	250
>100	500

Patient dose (in mg) ÷ 5 mg/mL = Number of mL of reconstituted Fabrazyme required for patient dose

Example: Patient dose = 80 mg

80 mg ÷ 5 mg/mL = 16 mL of Fabrazyme

Slowly withdraw the reconstituted solution from each vial up to the total volume required for the patient dose. Inject the reconstituted Fabrazyme solution directly into the Sodium Chloride solution. Do not inject in the airspace within the infusion bag. Discard any vial with unused reconstituted solution.

5. Gently invert infusion bag to mix the solution, avoiding vigorous shaking and

agitation.

6. Fabrazyme should not be infused in the same intravenous line with other products.

7. The diluted solution may be filtered through an in-line low protein-binding 0.2 μm filter during administration.

Storage

Store Fabrazyme under refrigeration between 2°-8°C (36°-46°F). DO NOT USE Fabrazyme after the expiration date on the vial.

Reconstituted and diluted solutions of Fabrazyme should be used immediately. This product contains no preservatives. If immediate use is not possible, the reconstituted and diluted solution may be stored for up to 24 hours at 2°-8°C (36°-46°F).

HOW SUPPLIED

Fabrazyme is supplied as a sterile, nonpyrogenic, white to off-white lyophilized cake or powder. Fabrazyme 35 mg vials are supplied in single-use, clear Type I glass 20 mL (cc) vials. The closure consists of a siliconized butyl stopper and an aluminum seal with a plastic purple flip-off cap. Fabrazyme 5 mg vials are supplied in single use, clear Type I glass 5 mL (cc) vials. The closure consists of a siliconized butyl stopper and an aluminum seal with a plastic gray flip-off cap.

35 mg vial: NDC 58468-0040-1
5 mg vial: NDC 58468-0041-1

Rx Only
U.S. Patent Number: 5,356,804

Fabrazyme is manufactured and distributed by:
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
1-800-745-4447 (phone)

U.S. License Number: 1596

Issued: TBD